These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 86627

  • 1. [Clinical experience with pepleomycin (NK 631) (author's transl)].
    Hashimoto K, Shioda S, Amagasa T, Shimizu M, Sato O, Ito H, Fujibayashi T, Soda T.
    Jpn J Antibiot; 1979 Mar; 32(3):451-62. PubMed ID: 86627
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical effects of NK 631 in malignant tumors of the oral cavity (author's transl)].
    Kawahira K, Dohhara Y, Sugihara K, Yamada K, Fujinami Y, Saku T, Yamashita S.
    Jpn J Antibiot; 1979 Jan; 32(1):138-48. PubMed ID: 84884
    [No Abstract] [Full Text] [Related]

  • 3. [Preoperative application of NK 631 for carcinoma of oral cavity (author's transl)].
    Yamamoto E, Sunakawa H, Kohama GI.
    Jpn J Antibiot; 1979 Feb; 32(2):253-8. PubMed ID: 86621
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical experiences with pepleomycin (NK 631) (author's transl)].
    Kusakari J, Sato Y, Saijo S, Tomioka S, Kawamoto K.
    Jpn J Antibiot; 1978 Nov; 31(11):659-63. PubMed ID: 83402
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Clinical effects of NK 631, a new bleomycin derivative, in treatment of oral cancer (author's transl)].
    Kajiyama M, Dohjyo M, Ohno A, Nagasaka K, Yamaguma M, Okabe T, Terasaka S.
    Jpn J Antibiot; 1979 Jan; 32(1):129-37. PubMed ID: 84883
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical experience with NK 631 in malignant tumors of skin (author's transl)].
    Nobe O, Kubo H, Yoshii K, Tashiro M.
    Jpn J Antibiot; 1979 Mar; 32(3):463-9. PubMed ID: 86628
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical application of NK 631 to head-and-neck cancers (author's transl)].
    Ogawa Y, Omata T, Imaizumi H, Shiga H, Ouchi J.
    Jpn J Antibiot; 1979 Jan; 32(1):115-20. PubMed ID: 84881
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical application of NK 631, a new derivative of bleomycin (author's transl)].
    Asahi M.
    Jpn J Antibiot; 1979 Jul; 32(7):744-50. PubMed ID: 90742
    [Abstract] [Full Text] [Related]

  • 19. [Technique and clinical assessment of the intra-arterial chemotherapy of squamous cell carcinoma (author's transl)].
    Günther R, Müller W.
    Arch Geschwulstforsch; 1982 Jul; 52(2):113-6. PubMed ID: 6179496
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of oral and maxillofacial squamous cell carcinomas by zhenguangmycin---with discussion on the similarities and differences between zhenguangmycin and bleomycin (author's transl)].
    Zhonghua Kou Qiang Ke Za Zhi; 1979 Jun; 14(2):77-9. PubMed ID: 95503
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.